daraxonrasib
PulseAugur coverage of daraxonrasib — every cluster mentioning daraxonrasib across labs, papers, and developer communities, ranked by signal.
- 2026-06-08 product_launch Daraxonrasib showed significant positive results in a Phase 3 trial for pancreatic cancer, doubling survival duration. source
- 2026-05-31 research_milestone A new drug, daraxonrasib, demonstrated a significant increase in survival time for advanced pancreatic cancer patients in a clinical trial. source
1 day(s) with sentiment data
-
RAS-targeted therapies show promise for new cancer treatments
CITIC Securities has released a research report highlighting the potential of RAS-targeted therapies in oncology. These therapies aim to unlock previously undruggable targets within the RAS gene family, which includes K…
-
New antibody treatment targets hard-to-reach pancreatic cancer protein
Researchers have developed a novel experimental treatment for pancreatic cancer that targets a difficult-to-reach protein deep within cells. This new approach uses carrier particles to deliver antibodies inside the cell…
-
Daraxonrasib doubles survival for pancreatic cancer patients
Daraxonrasib, a new drug developed by Revolution Medicines, has shown significant promise in treating pancreatic ductal adenocarcinoma, a notoriously deadly cancer. In a Phase 3 trial, the drug doubled survival duration…
-
Experimental pill nearly doubles survival for advanced pancreatic cancer
A new experimental pill, daraxonrasib, has shown significant promise in treating advanced pancreatic cancer by targeting a mutated protein that fuels tumor growth. In a study, patients taking the daily pill nearly doubl…